Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
2,061 to 2,080 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| METTL3-Mediated m6A RNA Methylation of ZBTB4 Interferes With Trophoblast Invasion and Maybe Involved in RSA. | Front Cell Dev Biol | 2022 | 35774226 | PubTator, text mining | PubMed |
| N(6)-methyladenosine methylation-regulated polo-like kinase 1 cell cycle homeostasis as a potential target of radiotherapy in pancreatic adenocarcinoma. | Sci Rep | 2022 | 35773310 | PubTator, text mining | PubMed |
| circRNA: Regulatory factors and potential therapeutic targets in inflammatory dermatoses. | J Cell Mol Med | 2022 | 35770323 | PubTator, text mining | PubMed |
| Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments. | Front Cardiovasc Med | 2022 | 35770215 | PubTator, text mining | PubMed |
| A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma. | Front Immunol | 2022 | 35769464 | PubTator, text mining | PubMed |
| Limited effects of m6A modification on mRNA partitioning into stress granules. | Nat Commun | 2022 | 35768440 | PubTator, text mining | PubMed |
| DNA methyltransferase 1 knockdown reverses PTEN and VDR by mediating demethylation of promoter and protects against renal injuries in hepatitis B virus-associated glomerulonephritis. | Cell Biosci | 2022 | 35765066 | PubTator, text mining | PubMed |
| m6A demethylase ALKBH5 is required for antibacterial innate defense by intrinsic motivation of neutrophil migration. | Signal Transduct Target Ther | 2022 | 35764614 | PubTator, text mining | PubMed |
| Construction and validation of an m6A RNA methylation regulator prognostic model for early-stage clear cell renal cell carcinoma. | Oncol Lett | 2022 | 35761938 | PubTator, text mining | PubMed |
| WTAP-mediated N6-methyladenosine modification of NLRP3 mRNA in kidney injury of diabetic nephropathy. | Cell Mol Biol Lett | 2022 | 35761192 | PubTator, text mining | PubMed |
| CORRIGENDUM. | Clin Transl Med | 2022 | 35758321 | PubTator, text mining | PubMed |
| N(6)-methyladenosine-mediated miR-380-3p maturation and upregulation promotes cancer aggressiveness in pancreatic cancer. | Bioengineered | 2022 | 35758158 | PubTator, text mining | PubMed |
| Ibuprofen promotes p75 neurotrophin receptor expression through modifying promoter methylation and N6-methyladenosine-RNA-methylation in human gastric cancer cells. | Bioengineered | 2022 | 35758042 | PubTator, text mining | PubMed |
| Mechanism of Ferroptosis and Its Role in Spinal Cord Injury. | Front Neurol | 2022 | 35756929 | PubTator, text mining | PubMed |
| Expression and Clinical Significance of the m6A RNA-Binding Proteins YTHDF2 in Peripheral Blood Mononuclear Cells From New-Onset Ankylosing Spondylitis. | Front Med (Lausanne) | 2022 | 35755020 | PubTator, text mining | PubMed |
| The Alteration of m6A Modification at the Transcriptome-Wide Level in Human Villi During Spontaneous Abortion in the First Trimester. | Front Genet | 2022 | 35754822 | PubTator, text mining | PubMed |
| Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours. | Front Pharmacol | 2022 | 35754499 | PubTator, text mining | PubMed |
| MicroRNA-30c-2-3p represses malignant progression of gastric adenocarcinoma cells via targeting ARHGAP11A. | Bioengineered | 2022 | 35754342 | PubTator, text mining | PubMed |
| Mechanisms and Strategies for Determining m6 A RNA Modification Sites by Natural and Engineered m6 A Effector Proteins. | Chem Asian J | 2022 | 35750635 | PubTator, text mining | PubMed |
| m6A in the Signal Transduction Network. | Mol Cells | 2022 | 35748227 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=104